Clinical Trial

Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Respiratory distress syndrome (RDS) is a common cause of respiratory failure in preterm infants and is frequently treated with surfactant therapy. With the increasing use of noninvasive ventilation, less invasive methods of surfactant administration have been developed. In the technique known as Less Invasive Surfactant Administration (LISA), surfactant is delivered into the trachea through a thin catheter, without the need for endotracheal intubation. This approach may reduce lung injury and improve respiratory outcomes in spontaneously breathing preterm infants. This multicenter, prospective, randomized study aims to compare the clinical effectiveness of poractant alfa and calfactant when administered using the LISA technique in preterm infants born at less than 30 weeks' gestation with RDS who are not intubated. The study will evaluate short-term outcomes, including the need for intubation, repeat surfactant administration, and respiratory support during the first 72 hours of life, as well as longer-term outcomes such as bronchopulmonary dysplasia and other neonatal morbidities.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-29
Trial Details
NCT Number NCT07350018
Lead Sponsor Uludag University
Conditions Respiratory Distress Syndrome in Premature Infants, Respiratory Distress Syndrome (RDS), Surfactant
Enrollment 234 participants
Start Date 2026-01-20
Primary Completion 2027-02-20 (estimated)
Study Completion 2027-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-04-28